User profiles for R. Stahel
 | Rolf StahelOncology, University of Züruch Verified email at usz.ch Cited by 36773 |
[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
Circulating DNA: a new diagnostic gold mine?
A Ziegler, U Zangemeister-Wittke, RA Stahel - Cancer treatment reviews, 2002 - Elsevier
The recent discovery that cell-free DNA can be shed into the bloodstream as a result of
tumour cell death has generated great interest. Numerous studies have demonstrated tumour-…
tumour cell death has generated great interest. Numerous studies have demonstrated tumour-…
[HTML][HTML] Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review
… In summary, concurrent EGF-R-targeting TKIs and extra-cranial SRT might be associated
with increased toxicity within the irradiated volume in the treatment of abdominal and thoracic …
with increased toxicity within the irradiated volume in the treatment of abdominal and thoracic …
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised …
…, D Ma, D Gill, J Walewski, PL Zinzani, R Stahel… - The lancet …, 2006 - thelancet.com
… ; R Stahel was the principal investigator in Switzerland, and designed the study; O Shpilberg
was the principal investigator in Israel, and designed the study; U Jaeger was the principal …
was the principal investigator in Israel, and designed the study; U Jaeger was the principal …
[HTML][HTML] DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Background Adjuvant cisplatin-based chemotherapy improves survival among patients with
completely resected non–small-cell lung cancer, but there is no validated clinical or biologic …
completely resected non–small-cell lung cancer, but there is no validated clinical or biologic …
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
…, B Baumann, SH Leech, D Fabbro, RA Stahel… - Cancer research, 2000 - AACR
Survivin, an inhibitor of apoptosis protein, deserves attention as a selective target for cancer
therapy because it lacks expression in differentiated adult tissues but is expressed in a …
therapy because it lacks expression in differentiated adult tissues but is expressed in a …
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised …
…, S Kvaloy, P de Nully Brown, R Stahel… - The lancet …, 2011 - thelancet.com
… no difference between R-CHOP-21 plus radiotherapy for bulky disease in the MInT study and
R-… Since dose escalation in the form of R-CHOEP alone was not superior to R-CHOP in the …
R-… Since dose escalation in the form of R-CHOEP alone was not superior to R-CHOP in the …
[HTML][HTML] EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
…, D Schadendorf, M van den Bent, J Seoane, R Stahel… - Annals of …, 2021 - Elsevier
Highlights • This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours. • The guideline covers clinical and …
patients with brain metastases from solid tumours. • The guideline covers clinical and …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of …
…, SM Keller, M Mauer, N Jha, R Stahel… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC).
We assessed pembrolizumab as adjuvant therapy for completely resected stage IB…
We assessed pembrolizumab as adjuvant therapy for completely resected stage IB…